Denis Chem Lab

Which are the latest news on Denis Chem Lab?

Why is Denis Chem Lab Ltd falling/rising?

As of 30-Jul, Denis Chem Lab Ltd's stock price is slightly rising at 69.70, but it has underperformed significantly over the past year with a -29.95% return and declining investor interest. Despite a minor uptick today, the stock shows a bearish trend and weak long-term fundamentals.

As of 30-Jul, Denis Chem Lab Ltd's stock price is experiencing a slight rise, currently at 69.70, with a change of 0.03 (0.04%) upward. However, this minor increase comes after a period of consecutive declines, as the stock has been losing for the last three days, resulting in a total drop of -1.9% during that timeframe. <BR><BR>In terms of performance relative to the market, Denis Chem Lab has underperformed significantly over various periods, including a -29.95% return over the past year, which is starkly contrasted by the BSE500's performance. The stock has also shown negative returns over the past week and month, with declines of -2.29% and -6.88%, respectively. <BR><BR>Investor participation appears to be waning, as indicated by a delivery volume of 14.75 k on 29 July, which has decreased by -26.57% compared to the 5-day average. Additionally, the stock is trading below its moving averages across multiple timeframes, suggesting a bearish trend.<BR><BR>Despite having a relatively attractive valuation with a ROE of 9.2 and a Price to Book Value of 1.1, the company has shown weak long-term fundamental strength, with a CAGR growth in net sales of only 10.70% over the last five years. Furthermore, the latest quarterly results indicate a significant drop in profit after tax (PAT) by -81.7% compared to the previous four-quarter average, and the earnings per share (EPS) is at its lowest at Rs 0.29.<BR><BR>Overall, while there is a slight uptick in the stock price today, the broader context reveals a concerning trend of underperformance and declining investor interest, which suggests that the stock is more likely to face continued pressure in the near term.

Should I buy, sell or hold Denis Chem Lab Ltd?

How big is Denis Chem Lab?

As of 10th June, Denis Chem Lab Ltd has a market capitalization of 102.00 Cr, with recent net sales of 181.72 Cr and a net profit of 8.41 Cr. The company reported shareholder's funds of 85.10 Cr and total assets of 112.27 Cr for the latest annual period ending in March 2025.

As of 10th June, Denis Chem Lab Ltd has a market capitalization of 102.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Denis Chem Lab reported Net Sales of 181.72 Cr and a Net Profit of 8.41 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 85.10 Cr and Total Assets of 112.27 Cr.

Who are in the management team of Denis Chem Lab?

The management team of Denis Chem Lab includes Dinesh B Patel (Chairman), Himanshu C Patel (Managing Director), Gaurang Dalal, Anar H Patel, Gauri Trivedi, and Hemendrakumar C Shah, all serving in various director roles.

The management team of Denis Chem Lab includes the following individuals:<BR><BR>1. **Dinesh B Patel** - Chairman & Non-Executive Director<BR>2. **Himanshu C Patel** - Executive Director / Managing Director / Promoter<BR>3. **Gaurang Dalal** - Independent Non-Executive Director<BR>4. **Anar H Patel** - Non-Executive Director<BR>5. **Gauri Trivedi** - Independent Non-Executive Director<BR>6. **Hemendrakumar C Shah** - Independent Non-Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Denis Chem Lab?

Peers of Denis Chem Lab include Tyche Industries, Godavari Drugs, Concord Drugs, Pharmaids Pharma, Mercury Labs, Makers Labs, Sotac Pharma, Vaishali Pharma, and Balaxi Pharma. Denis Chem Lab shows excellent management and growth, while its 1-year return is -32.56%, better than Pharmaids Pharma's -52.99% but worse than Concord Drugs' 161.37%.

Peers: The peers of Denis Chem Lab are Tyche Industries, Godavari Drugs, Concord Drugs, Pharmaids Pharma, Mercury Labs, Makers Labs, Sotac Pharma, Vaishali Pharma, and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Tyche Industries, Denis Chem Lab, Mercury Labs, and Balaxi Pharma, while Average management risk is found at Godavari Drugs and the rest. Below Average management risk is noted for Concord Drugs, Pharmaids Pharma, Makers Labs, and Sotac Pharma. In terms of Growth, Excellent growth is seen at Denis Chem Lab, while Below Average growth is present at Tyche Industries, Godavari Drugs, Concord Drugs, Pharmaids Pharma, Mercury Labs, Makers Labs, Vaishali Pharma, and Balaxi Pharma, and Average growth is noted at Sotac Pharma. For Capital Structure, Excellent capital structure is observed at Tyche Industries, Denis Chem Lab, Mercury Labs, and Balaxi Pharma, while Below Average capital structure is found at Godavari Drugs, Concord Drugs, Pharmaids Pharma, Makers Labs, and Vaishali Pharma, and Average capital structure is noted at Sotac Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Concord Drugs at 161.37%, while Pharmaids Pharma has the lowest at -52.99%. Denis Chem Lab's 1-year return is -32.56%, which is better than Pharmaids Pharma but worse than Concord Drugs. Additionally, the six-month return is negative for Pharmaids Pharma, Mercury Labs, and Makers Labs.

What does Denis Chem Lab do?

Denis Chem Lab Ltd manufactures sterile intravenous injectables and IV fluids, operating in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 47 Cr and a market cap of INR 102 Cr.

Overview: <BR>Denis Chem Lab Ltd is a company engaged in the manufacturing of sterile intravenous (IV) injectables and IV fluids, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Denis Chem Lab Limited was incorporated in 1980 and became a Public Limited Company in 1982. The company commenced commercial production of sterile IV injectables in 1984 and registered with the Directorate General of Technical Development for manufacturing IV fluids and bulk drugs. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 47 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 102 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Industry P/E: 36 <BR>Dividend Yield: 2.07% <BR>Debt Equity: -0.27 <BR>Return on Equity: 9.18% <BR>Price to Book: 1.10 <BR><BR>Contact Details: <BR>Address: Block No 457 Kalol Taluka, Chhatral Gandhinagar Gujarat : 382729 <BR>Tel: 91-2764-233596/233613 <BR>Email: denishchem401@gmail.com <BR>Website: http://www.denischemlab.com

Are Denis Chem Lab Ltd latest results good or bad?

Denis Chem Lab Ltd's latest results are concerning, with a 2.70% revenue increase overshadowed by an 81.70% drop in net profit and a significant contraction in operating margins. The stock has underperformed, declining 31.22% over the past year, leading to a "SELL" rating and negative investor sentiment.

Denis Chem Lab Ltd's latest results indicate a troubling performance. While the company reported a revenue increase of 2.70% quarter-on-quarter, its net profit plummeted by 81.70%, falling to just ₹0.40 crores. This sharp decline in profitability, despite revenue growth, raises significant concerns about the company's operational efficiency and margin sustainability.<BR><BR>The operating margin also contracted dramatically from 13.22% to 5.43%, reflecting severe margin compression and operational challenges. Additionally, the company's profit after tax (PAT) margin dropped to a mere 0.86%, indicating that it is struggling to convert sales into profit effectively.<BR><BR>Overall, the stock has underperformed significantly over the past year, declining 31.22%, which is much worse than the broader market and the pharmaceuticals sector. With a current rating of "SELL" and a score of 37 out of 100, investor sentiment appears to be quite negative, highlighting concerns about the sustainability of Denis Chem Lab's business model amidst these financial challenges.

When is the next results date for Denis Chem Lab Ltd?

The next results date for Denis Chem Lab Ltd is 30 May 2026.

The next results date for Denis Chem Lab Ltd is scheduled for 30 May 2026.

Is Denis Chem Lab overvalued or undervalued?

As of November 17, 2025, Denis Chem Lab is considered undervalued with a PE ratio of 16.73 and favorable valuation metrics compared to its industry peers, despite a recent stock underperformance of -47.04% against the Sensex.

As of 17 November 2025, Denis Chem Lab's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, given its PE ratio of 16.73, EV to EBIT of 8.73, and a Price to Book Value of 1.36. These metrics suggest that the company is trading at a reasonable valuation compared to its peers.<BR><BR>In comparison to its industry, Denis Chem Lab's PE ratio is significantly lower than that of Supreme Industries and Astral, which are both categorized as very expensive with PE ratios of 54.4 and 77.37, respectively. Additionally, the company's EV to EBITDA ratio of 5.94 is more favorable than the industry average, reinforcing its undervaluation status. While the stock has underperformed against the Sensex over the past year, with a return of -47.04% compared to the Sensex's 9.50%, the current valuation metrics suggest that there is potential for recovery and growth moving forward.

How has been the historical performance of Denis Chem Lab?

Denis Chem Lab has shown steady growth in net sales and profitability, with net sales increasing from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25, and profit after tax rising from 6.35 Cr to 8.08 Cr during the same period. The company has also improved its financial stability, reducing total debt significantly while maintaining positive cash flow.

Answer:<BR>The historical performance of Denis Chem Lab shows a steady growth in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Denis Chem Lab's net sales have increased from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25, reflecting a consistent upward trend. Total operating income has followed a similar trajectory, rising from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25. However, total expenditure has also increased, from 110.26 Cr in Mar'19 to 157.19 Cr in Mar'25, which has impacted operating profit, which peaked at 22.63 Cr in Mar'24 before declining to 18.48 Cr in Mar'25. Profit before tax has shown improvement from 5.92 Cr in Mar'19 to 11.11 Cr in Mar'25, while profit after tax has increased from 6.35 Cr in Mar'19 to 8.08 Cr in Mar'25. The company's total assets have grown from 97.42 Cr in Mar'20 to 112.27 Cr in Mar'25, alongside a decrease in total debt from 10.51 Cr in Mar'20 to 0.82 Cr in Mar'25, indicating improved financial stability. Cash flow from operating activities has fluctuated but remained positive, with a notable cash flow of 12.00 Cr in Mar'25. Overall, Denis Chem Lab has demonstrated a robust growth trajectory in sales and profitability, alongside a strengthening balance sheet.

What is the technical trend for Denis Chem Lab?

As of April 30, 2025, Denis Chem Lab's trend is mildly bearish, influenced by daily moving averages and weekly Bollinger Bands, though the weekly MACD is mildly bullish and the monthly RSI is bullish, indicating mixed momentum and a weak bearish sentiment with potential for recovery.

As of 30 April 2025, the technical trend for Denis Chem Lab has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing bearish signals. The MACD on a weekly basis is mildly bullish, providing some counterbalance, while the monthly MACD remains mildly bearish. The RSI on a monthly basis is bullish, but with no signal on the weekly, indicating mixed momentum. Overall, the indicators suggest a weak bearish sentiment with some signs of potential recovery in the longer term.

Who are the top shareholders of the Denis Chem Lab?

The top shareholders of Denis Chem Lab are Anar Himanshu Patel with 21.7%, V-s Holding B.v. at 20.74%, and individual investors holding a combined 27.41%. There are no institutional or pledged promoter holdings reported.

The top shareholders of Denis Chem Lab include Anar Himanshu Patel, who holds the largest share at 21.7%. Following him is V-s Holding B.v., with a stake of 20.74%. Additionally, individual investors collectively hold 27.41% of the company's shares. There are no institutional holdings or pledged promoter holdings reported.

Has Denis Chem Lab declared dividend?

Yes, Denis Chem Lab Ltd has declared a 25% dividend, amounting to 2.5 per share, with an ex-date of September 19, 2024. While recent returns have been negative, the company has shown significant growth over the longer term, particularly with a total return of 234.06% over the past five years.

Denis Chem Lab Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 2.37%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -36.1%, the dividend return was 0%, resulting in a total return of -36.1%.<BR><BR>Over the past year, the price return was -37.61%, the dividend return was 1.39%, leading to a total return of -36.22%.<BR><BR>In the 2-year period, the price return was 35.7%, the dividend return was 4.70%, which resulted in a total return of 40.4%.<BR><BR>For the last 3 years, the price return was 86.63%, the dividend return was 11.78%, culminating in a total return of 98.41%.<BR><BR>Over the past 4 years, the price return was 59.07%, the dividend return was 12.70%, resulting in a total return of 71.77%.<BR><BR>In the 5-year period, the price return was 213.91%, the dividend return was 20.15%, leading to a total return of 234.06%.<BR><BR>Overall, Denis Chem Lab Ltd has declared a dividend, and while recent returns have been negative in the shorter term, the longer-term returns show significant growth, particularly in the 5-year period.